ClinicalTrials.gg
RecruitingNCT06625671Updated Jun 2, 2026

A Phase 1/2a Study of DB-2304 in Healthy Adults and SLE/CLE Participants

A Phase 1/2 interventional study of DB-2304 and Placebo in Systemic Lupus Erythematosus (SLE) or Cutaneous Lupus Erythematosus, sponsored by DualityBio Inc.. Recruiting at 7 sites in 2 countries. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-02.

Sponsored by DualityBio Inc. · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2024; still recruiting 2 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
148
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 477 studies in Lupus Erythematosus, Systemic with a site in United States — 87 open to participants now, 127 under way, 28 of them phase 3. Lupus Erythematosus, Systemic · United States.

Planned enrollment
144th of 407
148 · median 70
Started
2024
with 32 others
Phase 1/2
26 of 477
8 open now
Primary completion
2027-06
later than 44 of 125 live
Registered
419th of 477
by date

Among the 477 studies in Lupus Erythematosus, Systemic with a site in United States, this one is the 144th largest by planned enrollment of the 407 interventional ones that give a count, is one of 33 that started in 2024, is one of 26 in phase 1/2, reaches primary completion later than 44 of the 125 other live ones, and was the 419th registered.

Lupus Erythematosus, Systemic

1,211 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

87 of the 477 studies in Lupus Erythematosus, Systemic with a site in United States are open now. Recruiting first, the newest first:

82 more — sign in →

All 87 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 94 (33%) set no upper age limit and 160 (56%) stop at 75 or younger; 54 take children under 18; 32 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 477 studies in Lupus Erythematosus, Systemic with a site in United States, or all of them as a file.
02

Study summary

A Phase 1/2a Study of DB-2304 in Healthy Participants and Participants with Systemic Lupus Erythematosus or Cutaneous Lupus Erythematosus

03

Conditions studied

  • Systemic Lupus Erythematosus (SLE) or Cutaneous Lupus Erythematosus
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria (Part A):

  1. Participants who fully understand the purpose, nature, method, and potential adverse reactions of the study and voluntarily sign the form (ICF) and agree to participate.
  2. Healthy male or female participants; 18 to 55 years of age (both inclusive) on the day of signing ICF; meet the (BMI) criteria.
  3. Based on the investigator assessment, there are no abnormal findings or findings with clinical significance from the medical history consultation, physical examination, vital signs assessment, clinical laboratory tests, and 12-lead .
  4. Female participants of or male participants agree to use highly effective during the study.
  5. Participants who are willing and able to comply with the prescribed protocol treatment and evaluations

Inclusion Criteria (Part B):

  1. Participants who fully understand the purpose, nature, method, and potential adverse reactions of the study and voluntarily sign the informed consent form (ICF) and agree to participate.
  2. Participants who are willing and able to comply with the prescribed protocol treatment and evaluations.
  3. Male or female participants, 18 to 70 years of age (both inclusive) on the day of signing ICF.
  4. Currently receiving a stable SLE/CLE treatment regimen of any medication for a period of at least 1 month prior to randomization.

For SLE: 4. Meet the European Alliance of Associations for Rheumatology (EULAR)/American College of Rheumatology (ACR) 2019 classification criteria for SLE.

5. History or presence at Screening of positive antinuclear antibodies (ANA) or anti-double-stranded DNA (anti-dsDNA) antibodies.

6. At screening have active lupus skin disease defined by the SELENA-SLEDAI at screening and randomization.

For CLE: 8. Must have diagnosis of CLE that has been confirmed, with or without systemic LE manifestations.

9.Must have active CLE despite an adequate trial of conventional therapies.

Exclusion Criteria (Part A):

  1. Evidence or history of diseases.
  2. History of herpes zoster (shingles) or recurrent herpes simplex (e.g., oral cold sores or gen-ital sores).
  3. Any active or suspected bacterial, viral, fungal, or parasitic infection within 30 days prior to dosing.
  4. History of sensitivity to any ingredients of DB-2304.
  5. Participants who have undergone surgery within the past 3 months or have plans for sur-gery during the study.

Exclusion Criteria (Part B):

  1. Have active lupus nephritis or moderate-to-severe or chronic kidney disease
  2. Have active neuropsychiatric SLE within 8 weeks prior to screening
  3. Any active skin conditions or active arthritis other than SLE that may interfere with skin or arthritis assessments (e.g., psoriasis, non-LE skin lesions, non-LE alopecia areata, drug-induced lupus, rheumatoid arthritis) at screening.
  4. History of, or ongoing, malignant disease, including solid tumors and hematologic with the exception of basal cell carcinomas and squamous cell carcinomas and carcinoma in situ of the cervix that have been completely excised and considered cured >2 years prior to Screening.
  5. Known history of a primary immunodeficiency (e.g., common variable immunodeficiency syndrome), splenectomy, or any underlying condition that predisposes the participant to infection.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
148 participants (estimated)

Study arms

  • Experimental
    Dose Level 1

    Drug: DB-2304 · Drug: Placebo · Drug: Prednisone

  • Experimental
    Dose Level 2

    Drug: DB-2304 · Drug: Placebo · Drug: Prednisone

  • Experimental
    Dose Level 3

    Drug: DB-2304 · Drug: Placebo · Drug: Prednisone

  • Experimental
    Dose Level 4

    Drug: DB-2304 · Drug: Placebo · Drug: Prednisone

  • Experimental
    Dose Level 5

    Drug: DB-2304 · Drug: Placebo · Drug: Prednisone

  • Experimental
    Dose Level 6

    Drug: DB-2304 · Drug: Placebo

  • Experimental
    Dose Level 7

    Drug: DB-2304 · Drug: Placebo

  • Experimental
    Dose Level 8

    Drug: DB-2304 · Drug: Placebo

Interventions

  • DrugDB-2304

    DB-2304

  • DrugPlacebo

    Placebo

  • Prednisone

06

What researchers measure

Primary outcomes

  1. TEAEs

    Treatment-emergent adverse events

    Time frame: Up to 112 days after the study treatment administration for Part A, and up to 280 days after the first study treatment administration for Part B

  2. SAEs

    serious adverse events

    Time frame: Up to 112 days after the study treatment administration for Part A, and up to 280 days after the first study treatment administration for Part B

  3. ECG parameters

    12-lead electrocardiograms parameters including HR, PR, QT intervals, QTcF intervals for Fredericia's formula-QT corrected interval), and QRS duration should be determined.

    Time frame: Up to 112 days after the study treatment administration for Part A, and up to 280 days after the first study treatment administration for Part B

  4. Weight measurements

    Change and Rate of Change from Baseline in weight

    Time frame: Up to 112 days after the study treatment administration for Part A, and up to 280 days after the first study treatment administration for Part B

  5. Heart Rate measurements

    Change and Rate of Change from Baseline in heart rate

    Time frame: Up to 112 days after the study treatment administration for Part A, and up to 280 days after the first study treatment administration for Part B

  6. Pulse rate measurements

    Change and Rate of Change from Baseline in pulse rate

    Time frame: Up to 112 days after the study treatment administration for Part A, and up to 280 days after the first study treatment administration for Part B

  7. Respiratory rate measurements

    Change and Rate of Change from Baseline in respiratory rate

    Time frame: Up to 112 days after the study treatment administration for Part A, and up to 280 days after the first study treatment administration for Part B

  8. Body temperature measurements

    Change and Rate of Change from Baseline in body temperature

    Time frame: Up to 112 days after the study treatment administration for Part A, and up to 280 days after the first study treatment administration for Part B

07

Study locations

5 of 7 sites recruiting
  • US06-0
    La Palma, California 90623, United States
    Recruiting
  • US03-0
    Clearwater, Florida 33765, United States
    Recruiting
  • US05-0
    Orlando, Florida 32808, United States
    Recruiting
  • US08-0
    Syracuse, New York 13210, United States
    Not yet recruiting
  • US04-0
    Irving, Texas 75061, United States
    Recruiting
  • US02-0
    San Antonio, Texas 78215, United States
    Recruiting
  • Site AUS01-0
    Melbourne, Victoria 3004, Australia
    Completed

    Not enrolling at this site.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Jun 2027, 32 months after the start.

Of 38 phase 1/2 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 60. This study's planned 32 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 20, 2024
First posted
Oct 3, 2024
StartActual
Oct 4, 2024
Primary completionEst.
Jun 30, 2027
CompletionEst.
Dec 30, 2027
Last update
Jun 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06625671
Lead sponsor
DualityBio Inc.
Responsible party
Sponsor
First posted
Oct 3, 2024
Start date
Oct 4, 2024
Primary completion
Jun 30, 2027 (estimated)
Completion
Dec 30, 2027 (estimated)
Last update
Jun 2, 2026

Study contacts

Sally Li
Contact
sally.li@dualitybiologics.com
+86 13910863858
Cong Zhang
Contact
Lily Hu
study director · DualityBio Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion